Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730190) titled 'A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors' on July 22.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Condition:
Advanced Malignancies
Intervention:
Drug: TQB6426 for Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 2026
Target Sample Size: 151
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.go...